Targeting angiotensinogen with RNA-based therapeutics

Area of Science:

• Cardiovascular Medicine
• RNA Therapeutics
• Molecular Biology

Background:

• Cardiovascular diseases (CVDs) remain a leading cause of mortality worldwide.
• The renin-angiotensin-aldosterone system (RAAS) plays a critical role in regulating blood pressure and cardiovascular function.
• Angiotensinogen (AGT) is the precursor to angiotensin peptides within the RAAS.

Purpose of the Study:

• To review current data on RNA-based therapeutics targeting angiotensinogen.
• To evaluate the potential of AGT inhibition for treating cardiovascular diseases and other conditions.
• To summarize the preclinical efficacy and future research directions for AGT-targeted RNA therapeutics.

Main Methods:

• Review of existing literature on antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) targeting AGT.
• Analysis of preclinical data from animal models of hypertension, atherosclerosis, polycystic kidney disease, and pulmonary fibrosis.
• Evaluation of the pharmacokinetic and pharmacodynamic properties of liver-targeted AGT RNA therapeutics.

Main Results:

• Liver-targeted ASOs and siRNAs effectively suppress AGT expression.
• Promising results observed in animal models, including significant reductions in blood pressure and disease progression.
• Potential for infrequent dosing (e.g., a few injections per year) due to long-lasting effects, improving patient adherence.

Conclusions:

• Targeting AGT with RNA-based therapeutics represents a promising new strategy for managing hypertension and other diseases.
• The long duration of action is a key advantage, potentially overcoming challenges with medication adherence.
• Further research is needed to optimize AGT suppression levels, assess synergy with existing RAAS blockers, and evaluate safety in comorbid conditions.